S81 L and G170R mutations causing Primary Hyperoxaluria Type I in homozygosis and heterozygosis: an example of positive interallelic complementation. by Montioli, R et al.
	  	  
	  
This	  is	  an	  author	  version	  of	  the	  contribution	  published	  on:	  
Questa	  è	  la	  versione	  dell’autore	  dell’opera:	  
	  [Hum	  Mol	  Genet.	  2014	  Jul	  2.	  pii:	  ddu329]	  
ovvero	  	  
[Montioli	  R,	  Roncador	  A,	  Oppici	  E,	  Mandrile	  G,	  Giachino	  DF,	  Cellini	  B,	  Voltattorni	  CB.	  	  
	   S81	  L	  and	  G170R	  mutations	  causing	  Primary	  Hyperoxaluria	  Type	  I	  in	  homozygosis	  
and	  heterozygosis:	  an	  example	  of	  positive	  interallelic	  complementation.	  Hum	  Mol	  Genet.	  
2014	  Jul	  2.	  pii:	  ddu329.	  [Epub	  ahead	  of	  print]]	  
The	  definitive	  version	  is	  available	  at:	  
La	  versione	  definitiva	  è	  disponibile	  alla	  URL:	  
[http://hmg.oxfordjournals.org/content/early/2014/07/04/hmg.ddu329.long]	  
S81L	   AND	   G170R	   MUTATIONS	   CAUSING	   PRIMARY	   HYPEROXALURIA	   TYPE	   I	   IN	   HOMOZYGOSIS	   AND	  
HETEROZYGOSIS:	  AN	  EXAMPLE	  OF	  POSITIVE	  INTERALLELIC	  COMPLEMENTATION	  
	  
Riccardo	  Montioli1*,	  Alessandro	  Roncador1*,	  Elisa	  Oppici1,	  Giorgia	  Mandrile2,	  Daniela	  Francesca	  Giachino2,	  
Barbara	  Cellini1†	  and	  Carla	  Borri	  Voltattorni1	  
	  
1Department	  of	  Life	  Sciences	  and	  Reproduction	  ,	  University	  of	  Verona,	  Italy,	  2Department	  of	  Clinical	  &	  
Biological	  Sciences,	  University	  of	  Torino,	  Italy	  
	  
*The	  authors	  wish	  it	  to	  be	  known	  that,	  in	  their	  opinion,	  the	  first	  two	  authors	  should	  be	  regarded	  as	  joint	  
First	  Authors	  
	  
†	  To	  whom	  correspondence	  should	  be	  addressed:	  Dr.	  Barbara	  Cellini,	  Department	  of	  Life	  Sciences	  and	  
Reproduction	  (Section	  of	  Biological	  Chemistry),	  University	  of	  Verona	  (Italy),	  Strada	  Le	  Grazie,	  8,	  Verona.	  Tel:	  

















Primary	   hyperoxaluria	   type	   I	   (PH1)	   is	   a	   rare	   disease	   due	   to	   the	   deficit	   of	   peroxisomal	   alanine:glyoxylate	  
aminotransferase	  (AGT),	  a	  homodimeric	  pyridoxal	  5’-­‐phosphate	  (PLP)	  enzyme	  present	  in	  humans	  as	  major	  
(Ma)	  and	  minor	  (Mi)	  allele.	  PH1-­‐causing	  mutations	  are	  mostly	  missense	  identified	  in	  both	  homozygous	  and	  
compound	  heterozygous	  patients.	  Until	  now,	  the	  pathogenesis	  of	  PH1	  has	  been	  only	  studied	  by	  approaches	  
mimicking	  homozygous	  patients,	  while	  the	  molecular	  aspects	  of	  the	  genotype-­‐enzymatic-­‐clinical	  phenotype	  
relationship	   in	   compound	   heterozygous	   patients	   are	   completely	   unknown.	   Here,	   for	   the	   first	   time,	   we	  
elucidate	   the	   enzymatic	   phenotype	   linked	   to	   the	   S81L	   mutation	   on	   AGT-­‐Ma,	   relative	   to	   a	   PLP	   binding	  
residue,	   and	   how	   it	   changes	  when	   the	  most	   common	  mutation	  G170R	  on	  AGT-­‐Mi,	   known	   to	   cause	  AGT	  
mistargeting	   without	   affecting	   the	   enzyme	   functionality,	   is	   present	   in	   the	   second	   allele.	   By	   using	   a	  
bicistronic	  eukaryotic	  expression	  vector,	  we	  demonstrate	  that	  (i)	  S81L-­‐Ma	  is	  mainly	  in	  its	  apo	  form	  and	  has	  
a	  significant	  peroxisomal	  localization,	  and	  (ii)	  S81L	  and	  G170R	  monomers	  interact	  giving	  rise	  to	  the	  G170R-­‐
Mi/S81L-­‐Ma	  holo-­‐form,	  which	   is	   imported	   into	   peroxisomes	   and	   exhibits	   an	   enhanced	   functionality	  with	  
respect	  to	  the	  parental	  enzymes.	  These	  data,	  integrated	  with	  the	  biochemical	  features	  of	  the	  heterodimer	  
and	  the	  homodimeric	  counterparts	   in	   their	  purified	  recombinant	   form	  (i)	  highlight	   the	  molecular	  basis	  of	  
the	  pathogenicity	  of	  S81L-­‐Ma,	  and	  (ii)	  provide	  evidence	  for	  a	  positive	  interallelic	  complementation	  between	  
the	   S81L	   and	   G170R	   monomers.	   Our	   study	   represents	   a	   valid	   approach	   to	   investigate	   the	   molecular	  




Liver	   peroxisomal	   alanine:glyoxylate	   aminotransferase	   (AGT)	   is	   a	   homodimeric	   pyridoxal-­‐5’-­‐phosphate	  
(PLP)-­‐dependent	   enzyme,	   which	   catalyzes	   the	   conversion	   of	   L-­‐alanine	   and	   glyoxylate	   to	   pyruvate	   and	  
glycine,	  respectively.	  AGT	  deficiency	  is	  responsible	  for	  Primary	  Hyperoxaluria	  Type	  I	  (PH1)	  (MIM	  259900),	  a	  
rare	  autosomal	  recessive	  disease	  with	  an	  estimated	  prevalence	  of	  1	  to	  3	  per	  million	  population	  in	  Europe	  
(1,	  2).	  In	  PH1	  patients	  glyoxylate	  accumulation	  and	  its	  conversion	  to	  the	  metabolic	  end	  product	  oxalate	  lead	  
to	   calcium	   oxalate	   (CaOx)	   supersaturation	   and	   precipitation	   as	   CaOx	   stones.	   This	   condition	  manifests	   as	  
urolithiasis	  and/or	  nephrocalcinosis,	  and,	   if	  untreated,	  as	  systemic	  oxalosis	  with	  CaOx	  deposition	   in	  many	  
organs	  (3).	  
The	  AGXT	   gene	  encoding	  AGT	   is	  present	   in	  human	  population	  as	   two	  haplotypes,	   the	   “major”	   (encoding	  
AGT-­‐Ma)	   and	   the	   “minor”	   (encoding	  AGT-­‐Mi),	   the	   latter	   characterized	  by	  a	  74-­‐bp	  duplication	   in	   intron	  1	  
and	  two	  point	  mutations	  causing	  the	  P11L	  and	  I340M	  amino	  acid	  substitutions	  (4).	  Most	  of	  the	  mutations	  
associated	   with	   PH1	   (more	   than	   150)	   are	   missense	   and	   concern	   residues	   spread	   over	   the	   entire	   3D	  
structure	   of	   the	   enzyme	   (5).	   Biochemical,	   bioinformatic	   and	   cell	   biology	   studies	   have	   revealed	   that	  
pathogenic	  mutations	  can	  either	  alter	  the	  AGT	  catalytic	  machinery	  (6-­‐9),	  and/or	  undermine	  the	  stability	  of	  
the	   folded	   conformation	   (10-­‐14)	   leading,	   in	   most	   cases,	   to	   protein	   aggregation	   and/or	   mitochondrial	  
mistargeting	  (15).	  Moreover,	  some	  mutations	  have	  only	  an	  impact	  on	  the	  apo-­‐form	  of	  the	  protein	  (12,	  16,	  
17).	  
Like	  in	  other	  recessive	  diseases,	  a	  substantial	  share	  of	  PH1	  patients	  are	  compound	  heterozygous	  expressing	  
two	   different	   AGT	   alleles.	   In	   these	   patients,	   interallelic	   complementation	   (IC)	   phenomena	   could	   occur,	  
leading	  to	  a	  phenotype	  less	  severe	  (positive	  IC)	  or	  a	  more	  severe	  (negative	  IC)	  than	  that	  of	  the	  homozygous	  
counterparts.	   IC	   effects	   arise	   from	   the	   combination	   of	   monomers	   bearing	   different	   mutations	   yielding	  
heterodimeric	  species	  with	   functional	  and/or	  structural	  properties	  different	   from	  the	  average	  of	   those	  of	  
parental	   homodimers.	   Until	   now,	   only	   “single	   protein”	   studies	   have	   been	   undertaken	   to	   investigate	   the	  
molecular	  pathogenesis	  of	  PH1,	  and	  the	  possible	  interplay	  between	  two	  different	  pathogenic	  mutations	  at	  
clinical	   and	   enzyme	   level	   has	   never	   been	   analyzed.	   Taking	   into	   account	   that	   many	   PH1	   patients	   are	  
compound	  heterozygous,	  the	  investigation	  of	  their	  heterozygous	  status	  is	  highly	  desirable	  and	  will	  possibly	  
further	  expand	  the	  phenotype	  spectrum	  of	  the	  disease.	  	  
Here	   we	   started	   from	   the	   clinical	   data	   on	   two	   PH1	   patients,	   one	   hemizygous	   for	   the	   S81L	   mutation	  
associated	   with	   the	   major	   allele,	   and	   the	   other	   compound	   heterozygous	   for	   the	   S81L	   mutation	   on	   the	  
major	   allele	   and	   the	  most	   common	  mutation	   in	   Caucasian	   patients,	   i.e.	   the	   G170R	   associated	   with	   the	  
minor	   allele.	   It	   is	   known	   that	   the	   G170R	   mutation	   does	   not	   affect	   the	   kinetic	   and	   coenzyme	   binding	  
properties	   of	   AGT	   (17),	   but	   causes	   a	   folding	   defect	   leading	   to	   an	   erroneous	   targeting	   to	   mitochondria,	  
where	  the	  enzyme	  cannot	  perform	  glyoxylate	  detoxification	  (18).	  The	  S81L	  pathogenic	  mutation	  has	  been	  
firstly	  identified	  by	  Williams	  et	  al	  (19).	  Ser81	  forms	  a	  hydrogen	  bond	  with	  the	  phosphate	  group	  of	  PLP	  and,	  
although	  the	  molecular	  defect	  of	  the	  S81L-­‐Ma	  variant	  is	  unknown,	  the	  mutation	  to	  Leu	  has	  been	  predicted	  
to	  mainly	  affect	  the	  coenzyme	  binding	  affinity	  (20).	  We	  used	  a	  bicistronic	  eukaryotic	  expression	  vector	  and	  
a	  dual	  vector	  prokaryotic	  expression	  strategy	  to	  study	  for	  the	  first	  time	  not	  only	  the	  consequences	  of	  the	  
S81L	  mutation	  on	  AGT,	  but	  also	  the	   interplay	  at	  molecular	  and	  cellular	   level	  between	  the	  G170R	  and	  the	  
S81L	  mutations.	  By	  investigating	  the	  effects	  of	  each	  mutation	  and	  of	  their	  combination	  on	  the	  expression	  
level,	  specific	  activity,	  subcellular	  localization,	  functionality	  as	  well	  as	  on	  the	  coenzyme	  binding	  affinity	  and	  
the	  kinetic	  and	  spectroscopic	  properties	  of	  AGT,	  we	  were	  able	  to	  (i)	  elucidate	  the	  molecular	  defects	  of	  the	  
S81L-­‐Ma	   variant,	   (ii)	   mimic	   in	   mammalian	   cells	   the	   natural	   heteroallelic	   state	   occurring	   in	   compound	  
heterozygous	  patients	  bearing	  the	  S81L	  and	  the	  G170R	  mutations,	  (iii)	  isolate	  and	  characterize	  the	  G170R-­‐
Mi/S81L-­‐Ma	  heterodimer,	  and	  (iv)	  provide	  evidence	  for	  a	  global	  positive	  IC	  effect	  between	  the	  G170R	  and	  





Clinical	   cases-­‐	   Patient	  1	   is	   a	  30-­‐year-­‐old	  Albanian	  male,	   affected	  by	  nephrolithiasis	   since	  age	  3.	   PH1	  was	  
diagnosed	  at	  age	  24	  (AGT	  activity	  in	  liver	  biopsy	  reduced	  to	  23%	  of	  normal).	  At	  diagnosis	  urography	  showed	  
atrophy	  of	  the	  right	  kidney	  and	  multiple	  stones	  in	  the	  left	  one.	  Serum	  creatinin	  was	  1.18	  mg/dL,	  creatinin	  
clearance	  86	  mL/min/1.73mq,	  urinary	  oxalate	  1.3	  mmol/24	  h	  and	  urinary	  glycolate	  830	  µmol/24	  h,	  plasma	  
oxalate	   8	   µmol/l,	   plasma	   glycolate	   5	   µmol/l.	   He	   had	   a	   good	   pyridoxine	   response	   (600	   mg/die):	   urinary	  
oxalate	  decreased	  to	  0.480	  mmol/24	  h	  and	  plasma	  oxalate	  to	  0.8	  µmol/l.	  At	  age	  32	  serum	  creatinin	  was	  1.5	  
mg/dL	   and	   urinary	   oxalate	   0.35	   mmol/die;	   no	   systemic	   oxalosis	   was	   present.	   AGXT	   gene	   sequencing	  
demonstrated	   compound	   heterozygosis	   for	   S81L	   and	   G170R	  mutations	   (on	  Major	   and	  Minor	   haplotype,	  
respectively).	  No	  kidney	  disease	  was	  reported	  in	  the	  family,	  nor	  consanguinity	  among	  parents.	  
Patient	   2	   is	   a	   15-­‐year-­‐old	   Serbian	   female;	   at	   11	   months	   she	   presented	   failure	   to	   thrive,	   anorexia	   and	  
recurrent	  kidney	  stones;	  at	  that	  time	  urinary	  oxalate	  was	  242	  mmol/24	  h.	  End	  stage	  renal	  disease	  (ESRD)	  
occurred	  at	  age	  11	  (serum	  creatinin	  1744	  µmol/l).	  Plasma	  oxalate	  was	  110	  µmol/l.	  At	  that	  time	  abdominal	  
ultrasound	   showed	   nephrocalcinosis	   and	   kidney	   volume	   reduction.	   She	   presented	   growth	   retardation	  
(height:	  <	  10°	  centile,	  weight:	  3-­‐10°	  centile),	  painful	  bone	  attacks	  and	   leg	  deformity	   (genu	  varum)	  due	  to	  
systemic	   oxalosis.	   At	   age	   15	   she	   developed	   hyperparathyroidism,	   mild	   left	   ventricular	   hypertrophy	   and	  
heart	   dilatation	   and	   non-­‐specific	   central	   irritation	   at	   electroencephalogram	   (no	   seizures	   referred).	   No	  
formal	   pyridoxine	   testing	  was	   performed.	   She	   underwent	   a	   combined	   kidney-­‐liver	   transplant	   at	   age	   15.	  
AGXT	   gene	   sequencing	   demonstrated	   compound	   heterozygosis	   for	   S81L	   and	   S205X	  mutations	   (both	   on	  
major	   haplotype).	   Thus,	   this	   patient	   can	   be	   considered	   “functionally	   hemizygous”	   for	   the	   non-­‐null	  
mutation,	  because	  it	  only	  expresses	  the	  allele	  bearing	  the	  S81L	  mutation.	  No	  kidney	  disease	  was	  reported	  
in	  the	  family,	  nor	  consanguinity	  among	  parents.	  
Based	  on	   these	  data,	  which	   indicate	  a	  different	   severity	  of	   the	   two	   cases,	  we	  decided	   to	   investigate	   the	  
enzymatic	  phenotype	  associated	  with	  the	  S81L	  mutation	  on	  the	  major	  allele	  as	  well	  as	   the	  occurrence	  of	  
possible	  IC	  effects	  between	  the	  S81L	  and	  the	  G170R	  mutation	  on	  the	  minor	  allele.	  To	  this	  aim,	  considering	  
the	   great	   variety	   of	   the	   molecular	   mechanisms	   leading	   to	   AGT	   deficiency	   in	   PH1,	   we	   studied	   the	  
consequences	   of	   each	  mutation	   alone	   and	   of	   their	   combination	   on	   (i)	   the	   protein	   expression	   level,	   the	  
specific	  activity,	   the	  subcellular	   localization	  and	   the	   functionality	  upon	  expression	   in	  a	  eukaryotic	   cellular	  
system,	  and	  (ii)	  the	  coenzyme	  binding	  affinity	  and	  the	  spectroscopic	  and	  kinetic	  features	  of	  purified	  variants	  
in	  the	  homodimeric	  and	  heterodimeric	  state.	  	  
S81L	  and	  G170R	  mutations	   in	  homozygous	  and	  heterozygous	   conditions:	   effect	   on	   the	  expression	   level	  
and	  the	  specific	  activity	  of	  AGT-­‐	  We	  investigated	  the	  cellular	  effects	  of	  the	  S81L	  mutation	  on	  AGT-­‐Ma	  both	  
in	   conditions	   mimicking	   a	   homozygous	   patient	   and	   in	   conditions	   mimicking	   a	   compound	   heterozygous	  
patient	  bearing	  the	  G170R	  mutation	  on	  AGT-­‐Mi	  in	  the	  second	  allele.	  To	  this	  aim,	  we	  constructed	  a	  series	  of	  
pIRES	  vectors	  that	  allowed	  us	  to	  express	  under	  the	  same	  transcript	  two	  copies	  of	  the	  AGT	  cDNA	  bearing	  the	  
analyzed	  polymorphic	  and	  pathogenic	  mutations	  in	  different	  combinations	  (Fig.	  1).	  To	  distinguish	  between	  
the	  first	  and	  the	  second	  gene	  product,	  we	  introduced	  a	  FLAG	  tag	  on	  the	  surface	  portion	  of	  the	   loop	  251-­‐
266,	  exactly	  between	  the	  residues	  254	  and	  255	  of	  the	  first	  gene	  product.	  The	  chosen	  site,	  away	  from	  both	  
the	  C-­‐terminal	  peroxisomal	   targeting	   sequence	  and	   the	  active	   site,	   is	   predicted	   to	  accommodate	   the	   tag	  
without	  generating	  significant	  steric	  hindrance.	  As	  shown	  in	  Fig.	  1,	  in	  the	  constructs	  encoding	  two	  different	  
enzymatic	   species,	   the	   FLAG	   tag	   was	   inserted	   on	   the	   background	   of	   the	  minor	   allele.	   This	   allows	   us	   to	  
detect	   only	   the	   product	   of	   the	   second	   allele	   by	   an	   antibody	   specific	   for	   the	   AGT-­‐Ma.	   Each	   vector	   was	  
transduced	   in	   CHO-­‐GO	   cells,	   which	   stably	   express	   glycolate	   oxidase	   (GO)	   and	   represent	   a	   widely	   used	  
cellular	  model	   for	   PH1	   (21).	   Preliminary	   transient	   transfection	  experiments	   showed	   that	   the	  presence	  of	  
the	   FLAG	   tag	   did	   not	   significantly	   affect	   the	   AGT	   expression	   level,	   the	   enzymatic	   activity	   and	   the	  
intracellular	   trafficking.	  Thus,	  CHO-­‐GO	  clones	   stably	  expressing	  each	  of	   the	  constructs	  were	   selected	  and	  
the	   levels	   of	   expressed	   AGT	  were	   analyzed	   by	   western	   blot.	   A	   double	   band	   responsive	   to	   the	   anti-­‐AGT	  
antibody,	  absent	   in	   the	  parental	  cells,	   is	  present	   in	  all	   the	  clones	   (Fig.	  2A	  and	  B).	  The	  band	  at	   the	  higher	  
molecular	  weight	  is	  also	  responsive	  to	  the	  anti-­‐FLAG	  antibody,	  thus	  confirming	  that	  the	  clones	  express	  both	  
AGT	   alleles.	   To	   investigate	   whether	   the	   co-­‐expression	   of	   the	   two	   allelic	   forms	   actually	   generates	  
heterodimeric	   species,	  we	   immunoprecipitated	   stably	   transfected	   CHO-­‐GO	   cells	   expressing	  AGT-­‐Mi/AGT-­‐
Mi,	   G170R-­‐Mi/G170R-­‐Mi,	   AGT-­‐Mi/AGT-­‐Ma	   and	   G170R-­‐Mi/S81L-­‐Ma	   with	   an	   anti-­‐FLAG	   antibody	   and	   we	  
detected	  the	  precipitated	  proteins	  by	  western-­‐blot	  using	  an	  antibody	  specific	  for	  AGT-­‐Ma	  (Fig.	  3).	  The	  anti-­‐
FLAG	  antibody	  pulled	  down	  a	  protein	  that	  reacted	  with	  the	  anti-­‐AGT-­‐Ma	  antibody	  only	  in	  the	  AGT-­‐Mi/AGT-­‐
Ma	  and	  G170R-­‐Mi/S81L-­‐Ma	  clones.	  This	  indicates	  the	  formation	  of	  heterodimeric	  species	  in	  these	  samples,	  
because	  the	  FLAG	  tag	  is	  present	  on	  the	  first	  allele,	  while	  the	  AGT-­‐Ma	  epitope	  in	  these	  constructs	  is	  encoded	  
by	   the	   second	  allele	   (Fig.	   1).	   	   These	  data	   validate	  our	  experimental	  model	   for	   the	   study	  of	   the	  S81L	  and	  
G170R	  mutations	  in	  heterozygous	  state	  and	  the	  evaluation	  of	  possible	  IC	  effects	  at	  cellular	  level.	  However,	  
these	  results	  should	  be	  interpreted	  with	  caution	  considering	  that	  the	  relative	  proportions	  of	  homodimeric	  
and	  heterodimeric	  species	  cannot	  be	  measured	  under	  these	  experimental	  conditions.	  	  
In	   line	   with	   previous	   data	   (15),	   the	   expression	   level	   of	   AGT-­‐Mi/AGT-­‐Mi,	   AGT-­‐Mi/AGT-­‐Ma	   and	   G170R-­‐
Mi/G170R-­‐Mi	  was	  about	  75,	  90	  and	  46%,	  respectively,	  that	  of	  AGT-­‐Ma/AGT-­‐Ma.	  Moreover,	  while	  the	  S81L	  
mutation	  did	  not	  significantly	  reduce	  the	  expression	  level	  of	  AGT-­‐Ma/AGT-­‐Ma,	  cells	  expressing	  the	  G170R-­‐
Mi/S81L-­‐Ma	  construct	  showed	  an	  AGT	  expression	  level	  equal	  to	  ~	  30%	  that	  of	  cells	  expressing	  AGT-­‐Mi/AGT-­‐
Ma	   (Fig.	   2A	   and	   B).	   Similar	   results	   were	   obtained	   in	   different	   clones	   expressing	   the	   G170R-­‐Mi/S81L-­‐Ma	  
construct,	   and	   real-­‐time	  PCR	  experiments	   did	  not	   reveal	   differences	  between	   the	   clones	   at	   transcription	  
level.	  Thus,	  the	  reduced	  AGT	  level	  in	  G170R-­‐Mi/S81L-­‐Ma	  transfectants	  should	  originate	  from	  a	  defect	  at	  the	  
protein	  level	  leading	  to	  an	  increased	  aggregation	  and/or	  degradation	  propensity	  of	  the	  heterodimeric	  form	  
with	  respect	  to	  the	  homodimers	  G170R-­‐Mi	  and	  S81L-­‐Ma.	   In	  this	  regard,	  we	  found	  that	   in	  cells	  expressing	  
the	  G170R-­‐Mi/S81L-­‐Ma	  construct	  (i)	  the	  ratio	  soluble/insoluble	  AGT	  does	  not	  significantly	  differ	  from	  that	  
of	   cells	   expressing	   the	   AGT-­‐Mi/AGT-­‐Ma	   construct,	   and	   (ii)	   no	   aggregates	   of	   AGT	   can	   be	   revealed	   upon	  
cross-­‐linking	  with	  bis-­‐N-­‐succinimidyl-­‐(pentaethyleneglyocol)	  ester.	   	  Thus,	   it	  can	  be	  suggested	  that	  the	   low	  
AGT	   expression	   level	   of	   the	   clone	   G170R-­‐Mi/S81L-­‐Ma	   could	   arise	   from	   an	   increased	   susceptibility	   to	  
degradation	   of	   the	   heterodimeric	   species	   with	   respect	   to	   the	   homodimers	   G170R-­‐Mi	   and	   S81L-­‐Ma	   (see	  
below).	  
We	   then	  measured	   the	   specific	   activity	   of	   each	   clone	   in	   the	   absence	   and	   presence	   of	   PLP	   in	   the	   assay	  
mixture,	   representing	   the	   amount	   of	   the	   holoenzyme	   and	   of	   the	   total	   active	   protein	   (apoenzyme	   plus	  
holoenzyme),	  respectively	  (Fig.	  2C).	  In	  the	  presence	  of	  PLP,	  the	  specific	  activity	  of	  AGT-­‐Mi/AGT-­‐Mi	  and	  AGT-­‐
Mi/AGT-­‐Ma	   was	   reduced	   by	   about	   35	   and	   20%	   with	   respect	   to	   that	   of	   AGT-­‐Ma/AGT-­‐Ma,	   while	   that	   of	  
G170R-­‐Mi/G170R-­‐Mi	  is	  reduced	  by	  about	  70%	  with	  respect	  to	  that	  of	  AGT-­‐Mi/AGT-­‐Mi,	  in	  line	  with	  previous	  
data	  on	  cellular	   lysates	   (15).	  Moreover,	   the	  specific	  activity	  of	  S81L-­‐Ma/S81L-­‐Ma	  was	  ~	  20%	  that	  of	  AGT-­‐
Ma/AGT-­‐Ma,	  while	   that	  of	  G170R-­‐Mi/S81L-­‐Ma	  was	  ~	  4%	   that	  of	  AGT-­‐Mi/AGT-­‐Ma.	  As	   compared	  with	   the	  
activity	  in	  the	  presence	  of	  added	  coenzyme,	  the	  specific	  activity	  of	  AGT-­‐Ma/AGT-­‐Ma,	  AGT-­‐Mi/AGT-­‐Mi,	  AGT-­‐
Mi/AGT-­‐Ma	  and	  G170R-­‐Mi/G170R-­‐Mi	  measured	   in	   the	  absence	  of	  PLP	  decreased	  by	  25-­‐30%,	  and	   that	  of	  
G170R-­‐Mi/S81L-­‐Ma	  decreased	  by	  40%,	  thus	  indicating	  that	  in	  these	  clones	  AGT	  is	  in	  large	  amount	  present	  
as	  holoenzyme.	  In	  contrast,	  the	  specific	  activity	  of	  S81L-­‐Ma/S81L-­‐Ma	  decreased	  by	  95%	  in	  the	  absence	  of	  
PLP	  in	  the	  assay	  mixture,	  thus	  revealing	  that	  this	  variant	  in	  the	  cell	  is	  almost	  entirely	  present	  as	  apoenzyme.	  	  
Overall,	   the	   data	   obtained	   in	   the	   CHO-­‐GO	   cellular	  model	   indicate	   that	   (i)	   the	   S81L-­‐Ma	   variant	   is	   almost	  
entirely	   present	   as	   apoenzyme	   in	   the	   cell	   and	   its	   reduced	   specific	   activity	   is	   not	   ascribable	   to	   a	   reduced	  
expression	  level,	  and	  (ii)	  when	  the	  S81L-­‐Ma	  and	  the	  G170R-­‐Mi	  variants	  are	  co-­‐expressed	  in	  the	  same	  cell,	  
the	  formed	  heterodimeric	  species	  are	  mainly	  present	  as	  holoenzymes,	  but	  the	  total	  AGT	  expression	  level	  is	  
lower	  than	  that	  of	  cells	  expressing	  homodimeric	  S81L-­‐Ma	  or	  G170R-­‐Mi.	  	  
S81L	  and	  G170R	  mutations	  in	  homozygous	  and	  heterozygous	  conditions:	  effect	  on	  the	  structural	  and	  the	  
functional	  properties	  of	  AGT-­‐Although	  the	  data	  obtained	  in	  CHO-­‐GO	  cells	  confirm	  the	  pathogenicity	  of	  the	  
mutations,	   they	   do	   not	   allow	   the	   identification	   of	   the	   molecular	   mechanisms(s)	   by	   which	   the	   S81L	  
mutation,	   both	   in	   homozygosis	   and	   in	   heterozygosis	   with	   the	   G170R	   mutation,	   generates	   the	   AGT	  
malfunction.	  To	  gain	  insights	  into	  this	  issue,	  the	  homodimer	  S81L-­‐Ma	  and	  the	  heterodimer	  G170R-­‐Mi/S81L-­‐
Ma	  were	   expressed	   in	  E.coli,	   purified	   and	   characterized.	   Their	   spectroscopic	   and	   kinetic	   properties	  were	  
compared	  with	  those	  of	  AGT-­‐Ma,	  AGT-­‐Mi	  and	  G170R-­‐Mi,	  previously	  studied	  (17).	  Absorbance,	  visible	  and	  
near-­‐UV	  CD	  spectra	  of	  S81L-­‐Ma	  and	  G170R-­‐Mi/S81L-­‐Ma	  in	  the	  holo-­‐form	  were	  similar	  to	  each	  other	  and	  to	  
the	  corresponding	  ones	  of	  AGT-­‐Ma,	  AGT-­‐Mi	  and	  G170R-­‐Mi.	  Nevertheless,	  while	  no	  significant	  changes	  were	  
observed	   in	  1-­‐anilino	  naphthalene	  sulphonic	  acid	   (ANS)	  emission	  fluorescence	  for	  the	  holo-­‐forms	  of	  AGT-­‐
Ma,	  AGT-­‐Mi,	  S81L-­‐Ma	  and	  G170R-­‐Mi,	  an	  about	  10-­‐fold	   increase	   in	  ANS	  emission	  fluorescence	  intensity	   in	  
the	   holoheterodimer	   G170R-­‐Mi/S81L-­‐Ma	   was	   observed	   (Fig.	   S4).	   This	   indicates	   that	   the	   heterodimeric	  
species	   displays	   an	   increased	   exposure	   of	   hydrophobic	   patches	   on	   its	   surface,	   thus	   suggesting	   that	   the	  
formation	  of	   the	  heterodimer	   causes	  a	   conformational	   change	  with	   respect	   to	   the	  homodimeric	   species.	  
Following	  this	  view,	  we	  can	  speculate	  that,	  as	  found	  for	  other	  proteins	  that	  fold	  in	  the	  cell	  cytosol	  (22),	  the	  
increased	   exposure	   of	   hydrophobic	   surfaces	   would	   possibly	   induce	   the	   proteasomal	   degradation	   of	   the	  
heterodimer	  by	  triggering	  the	  cellular	  quality	  control	  machinery.	  
The	  effect	  of	  the	  S81L	  mutation	  on	  the	  PLP	  binding	  affinity	  of	  the	  homodimer	  and	  the	  heterodimer	  was	  also	  
investigated.	  As	  expected,	   considering	   that	  Ser81	   is	  hydrogen-­‐bonded	  with	   the	  PLP	  phosphate,	   the	  S81L-­‐
Ma	  homodimer	  displayed	  a	  ~70-­‐fold	  increase	  in	  the	  equilibrium	  dissociation	  constant	  for	  PLP	  (KD(PLP))	  with	  
respect	  to	  AGT-­‐Ma	  (Table	  1).	  This	  explains	  why	  in	  CHO-­‐GO	  cells	  expressing	  the	  S81L-­‐Ma/S81L-­‐Ma	  construct	  
grown	  in	  a	  medium	  containing	  about	  0.3	  μM	  pyridoxine	  (a	  concentration	  even	  higher	  than	  that	  present	  in	  
human	  plasma	  (23)),	  the	  variant	  was	  almost	  completely	  present	  in	  the	  apo-­‐form.	  Unexpectedly,	  the	  G170R-­‐
Mi/S81L-­‐Ma	  heterodimer	   showed	  a	  KD(PLP)	   value	  about	  7-­‐fold	   lower	   than	   that	  predicted	  by	  averaging	   the	  
KD(PLP)	   values	   of	   the	   two	   parental	   enzymes	   (Table	   1).	   In	   trying	   to	   explain	   this	   result,	   we	   modelled	   the	  
putative	   dimeric	   structure	   of	   AGT	   through	   a	   crystallographic	   symmetry	   operation	   on	   the	   available	  
monomeric	  structure	   (pdb	   file	  1H0C,	   (5)).	   It	   revealed	  that	   the	  phosphate	  group	  of	  PLP	   in	  each	  active	  site	  
interacts	  with	  the	  Oβ	  of	  Ser81	  and	  with	  the	  peptidic	  N(s)	  of	  Gly82	  and	  His83	  of	  the	  one’s	  own	  subunit,	  and	  
with	  the	  Oδ	  of	  Tyr260	  and	  the	  peptidic	  N	  of	  Thr263	  of	  the	  neighbouring	  subunit	  (Fig.	  S1A).	  The	  Ser81→Leu	  
substitution	  (i)	  eliminates	  the	  H	  bonds	  that	  stabilizes	  the	  PLP	  binding,	   (ii)	   introduces	  a	  bulky	  hydrophobic	  
side	  chain	   in	  a	  polar	   region	  of	   the	   interface	  between	  the	  AGT	  monomers,	  and	  (iii)	  generates	  a	  significant	  
steric	  hindrance	  that	  could	  compromise	  the	  H-­‐bond	  between	  His262	  and	  Ser79	  of	  the	  neighbouring	  subunit	  
(Fig.	  S1B).	  This	  in	  turn	  can	  destabilize	  the	  loop	  251-­‐266	  and	  the	  stretch	  79-­‐83	  of	  the	  neighbouring	  subunit,	  
both	  involved	  in	  PLP	  binding.	  On	  these	  bases,	  the	  S81L	  mutation	  is	  predicted	  to	  directly	  affect	  the	  cofactor	  
binding	  to	  one	  subunit,	  but	  also	  to	  indirectly	  perturb	  the	  PLP	  binding	  pocket	  of	  the	  adjacent	  subunit.	  The	  
lack	  of	  this	  indirect	  effect	  in	  the	  heterodimer	  G170R-­‐Mi/S81L-­‐Ma	  may	  explain	  its	  PLP	  binding	  affinity	  higher	  
than	  that	  expected.	  	  
The	   steady-­‐state	   kinetic	   parameters	   reported	   in	   Table	   1	   show	   that	   the	   S81L-­‐Ma	   homodimer	   is	  
characterized	  by	  a	  3-­‐fold	  decrease	  in	  the	  kcat	  value	  with	  respect	  to	  AGT-­‐Ma,	  while	  the	  G170R-­‐Mi/S81L-­‐Ma	  
heterodimer	   displays	   a	   kcat	   value	   slightly	   lower	   than	   that	   predicted	   by	   averaging	   the	   kcat	   values	   of	   the	  
homodimeric	  counterparts.	  There	  were	  no	  significant	  differences	  in	  the	  KM	  values	  of	  the	  examined	  variants.	  
Taken together, these data provide evidence that (i) the S81L mutation mainly induces a functional 
defect, by reducing the AGT catalytic activity and strongly decreasing the coenzyme binding 
affinity, and (ii) the heterodimer G170R-Mi/S81L-Ma shows kcat and KD(PLP) values similar to or 
lower than, respectively, those derived by the average of the corresponding ones of the 
homodimeric counterparts.  
S81L	   and	  G170R	  mutations	   in	   homozygous	   and	   heterozygous	   conditions:	   effect	   on	   the	  AGT	   subcellular	  
localization-­‐	  The	  G170R	  mutation	  on	  the	  minor	  allele	  is	  known	  to	  cause	  the	  mitochondrial	  mistargeting	  of	  
AGT,	  due	  to	  the	  synergism	  between	  the	  polymorphic	  P11L	  mutation,	  	  generating	  a	  putative	  mitochondrial	  
targeting	  sequence	  (MTS),	  and	  the	  G170R	  mutation,	  which	  induces	  a	  folding	  defect	  on	  apodimeric	  AGT	  that	  
results	   in	   the	   formation	  of	  monomeric	   folding	   intermediates	  prone	   to	   interact	  with	  molecular	   chaperons	  
and	   compatible	   with	   the	   mitochondrial	   import	   (12,	   15,	   17,	   18,	   24,	   25).	   In	   fact,	   while	   peroxisomes	   can	  
import	   fully-­‐folded	   oligomeric	   proteins,	   mitochondria	   import	   species	   bearing	   a	   MTS	   in	   partly-­‐folded	  
monomeric	   conformation.	  Up	   to	   date,	   no	   information	   is	   available	   on	   the	   effect	   of	   the	   S81L	  mutation	   in	  
homozygosis	  and	  heterozygosis	  with	  G170R	  on	  the	  AGT	  subcellular	  localization.	  Thus,	  the	  stable	  clones	  of	  
CHO-­‐GO	  cells	   expressing	   the	   various	   constructs	  were	  analyzed	  by	   immunofluorescence	  microscopy	   (IFM)	  
both	   qualitatively,	   by	   evaluating	   the	   RGB	   profile	   of	   the	   images,	   and	   quantitatively,	   by	   determining	   the	  
Pearson	  coefficient	  of	  each	  sample	  (Fig.	  4,	  5,	  S2,	  S3	  and	  6).	  The	  Pearson	  coefficient	  can	  be	  used	  	  to	  estimate	  
the	  colocalization	  between	  two	  signals	  evaluating	  the	  correlation	  between	  the	  signal	  intensity	  of	  the	  same	  
pixel	   in	   two	   channels.	   It	   is	   generally	   accepted	   that	   only	   values	   greater	   than	   0.5	   are	   indicative	   of	   a	  
meaningful	  colocalization	  (26).	  As	  expected,	  the	  localization	  of	  AGT-­‐Ma/AGT-­‐Ma,	  AGT-­‐Mi/AGT-­‐Mi	  and	  AGT-­‐
Mi/AGT-­‐Ma	   was	   entirely	   peroxisomal	   (Fig.	   S2	   and	   S3),	   while	   that	   of	   G170R-­‐Mi/G170R-­‐Mi	   was	   entirely	  
mitochondrial	  (Fig.	  5	  and	  6).	  Although	  S81L-­‐Ma	  showed	  a	  significant	  peroxisomal	  localization,	  a	  portion	  of	  
the	   protein	   is	   present	   in	   the	   cell	   cytosol	   (Fig.	   6).	   Cross-­‐linking	   and	   size-­‐exclusion	   chromatography	  
experiments	  of	   lysates	  of	  cells	  expressing	  this	  variant	  allowed	  us	  to	  exclude	  that	  the	  cytosolic	   localization	  
was	   due	   to	   the	   formation	   of	   cytosolic	   aggregates	   not	   compatible	   with	   the	   peroxisomal	   import.	  
Nevertheless,	   considering	   that	   the	   S81L-­‐Ma	  homodimer	   is	   present	   in	   the	   cell	  mainly	   as	   apoenzyme,	   it	   is	  
possible	   to	  hypothesize	   that	   the	  S81L	  mutation	   induces	  a	  conformational	   change	  on	  apoAGT	  causing	   the	  
slowing	  down	  of	  the	  peroxisomal	  import.	  Indeed,	  the	  purified	  S81L-­‐Ma	  apovariant	  showed	  with	  respect	  to	  
apoAGT-­‐Ma:	   (i)	   a	   slightly	   lower	   intrinsic	   fluorescence	   emission	   intensity,	   (ii)	   a	   near-­‐UV	   CD	   spectrum	  
characterized	  by	  an	  identical	  signal	  at	  291	  nm,	  and	  by	  a	  completely	  lost	  signal	  at	  284	  nm,	  and	  (iii)	  a	  3-­‐fold	  
increased	   ANS	   emission	   fluorescence	   intensity	   (Fig.	   S4).	   We	   tried	   to	   favor	   the	   peroxisomal	   import	   by	  
culturing	   the	   cells	   expressing	   the	   S81L-­‐Ma/S81L-­‐Ma	   in	   the	   presence	   of	   100	   μM	   pyridoxine	   to	   favor	  
holoenzyme	  formation.	  However,	  only	  a	  partial	  reduction	  of	  the	  cytosolic	  amount	  of	  the	  protein	  could	  be	  
observed.	  
Interestingly,	  the	  quantitative	  analysis	  of	  the	  distribution	  of	  AGT	  in	  cells	  expressing	  the	  G170R-­‐Mi/S81L-­‐Ma	  
construct	   showed	  a	   significant	  peroxisomal	   localization	  as	  highlighted	  by	   staining	  with	  both	   the	  anti-­‐AGT	  
and	  the	  anti-­‐FLAG	  antibody	  (Pearson	  coefficient	  of	  0.55	  and	  0.53	  for	  the	  colocalization	  of	  the	  peroxisomal	  
marker	  with	  anti-­‐AGT	  or	  anti-­‐FLAG,	  respectively)	   (Fig.	  6).	   It	   is	  worth	  to	  point	  out	  that	  cells	  expressing	  the	  
G170R-­‐Mi/S81L-­‐Ma	   construct	   will	   produce	   S81L-­‐Ma/S81L-­‐Ma	   homodimers,	  G170R-­‐Mi/G170R-­‐Mi	  
homodimers	   and	  G170R-­‐Mi/S81L-­‐Ma	   heterodimers.	   However,	  since	   the	   FLAG	   epitope	   in	   the	   construct	   is	  
associated	   with	   the	   G170R-­‐Mi	   moiety,	   the	   staining	   with	   the	   anti-­‐FLAG	   antibody	  will	   only	   label	   G170R-­‐
Mi/G170R-­‐Mi	  homodimers	  (known	  to	  be	  targeted	  to	  mitochondria)	  and	  G170R-­‐Mi/S81L-­‐Ma	  heterodimers.	  
Therefore,	   the	   detection	   of	   the	   FLAG	   signal	   in	   the	   peroxisomes	   not	   only	   confirms	   the	   formation	   in	   an	  
appreciable	   amount	   of	   the	   G170R-­‐Mi/S81L-­‐Ma	   heterodimers	   but	   also	   indicates	   their	   localization	   into	  
peroxisomes.	  	  
S81L	  and	  G170R	  mutations	  in	  homozygous	  and	  heterozygous	  conditions:	  effect	  on	  the	  AGT	  functionality	  
A	   glycolate-­‐toxicity	   assay	  was	   used	   to	   assess	   the	  AGT	   functionality	   in	   the	   analysed	   clones.	   CHO-­‐GO	   cells	  
were	  treated	  with	  250	  μM	  glycolate	  for	  24	  h	  to	  allow	  the	  formation	  of	  peroxisomal	  glyoxylate	  by	  GO.	  Since	  
glyoxylate	   induces	  cell	  death,	  the	  ability	  to	  survive	   in	  the	  presence	  of	  glycolate	   is	  a	  direct	  measure	  of	  the	  
ability	   to	   detoxify	   peroxisomal	   glyoxylate.	   As	   shown	   in	   Fig.	   7,	   the	   protection	   against	   glycolate	   toxicity	   of	  
AGT-­‐Ma/AGT-­‐Ma,	  AGT-­‐Mi/AGT-­‐Mi	  and	  AGT-­‐Mi/AGT-­‐Ma	  was	  70-­‐100%	  that	  of	  untreated	  cells.	   The	  G170R	  
mutation	   reduced	   by	   about	   50%	   the	   protection	   afforded	   by	   AGT-­‐Mi/AGT-­‐Mi,	   while	   the	   S81L	   mutation	  
reduced	  by	  about	  80%	  the	  protection	  afforded	  by	  AGT-­‐Ma/AGT-­‐Ma.	  Finally,	   the	  cell	   line	  expressing	  both	  
variants	   has	   a	   viability	   equal	   within	   experimental	   error	   to	   that	   of	   cells	   expressing	   only	   the	   G170R-­‐Mi	  
variant.	  Thus,	  the	  amount	  of	  AGT	  able	  to	  detoxify	  glyoxylate	  in	  cells	  expressing	  both	  S81L-­‐Ma	  and	  G170R-­‐
Mi	  is	  equal	  to	  that	  of	  cells	  expressing	  only	  G170R-­‐Mi	  and	  higher	  than	  that	  of	  cells	  expressing	  S81L-­‐Ma.	  This	  
finding	   along	   with	   the	   coenzyme	   binding	   affinity	   and	   the	   subcellular	   localization	   of	   the	   heterodimer	   is	  
relevant	  for	  its	  functionality.	  
	  
Discussion	  
In	   rare	   recessive	   diseases	  many	   patients	   are	   compound	   heterozygous.	   Thus,	   their	   enzymatic	   phenotype	  
results	  from	  the	  combination	  of	  the	  effect(s)	  of	  each	  single	  mutation	  when	  heteromeric	  protein	  forms	  are	  
generated.	  Positive,	  negative	  or	  no	  IC	  effects	  are	  usually	  observed	  at	  the	  clinical	   level.	  These	  effects	  have	  
been	  also	  investigated	  at	  the	  molecular	  level	  for	  few	  diseases	  such	  as	  phenylketonuria,	  arginino	  succinate	  
lyase	  deficiency	   and	  hypogonadotropic	  hypogonadonism	   (27-­‐29).	   These	   studies	  have	  been	  performed	  by	  
looking	  to	  either	  the	  “in	  vitro”	  catalytic	  properties	  of	  the	  heteromeric	  proteins	  or	  the	  specific	  activity	  upon	  
coexpression	  of	   the	   two	  variants	   in	  yeast	  and	  bacterial	   systems.	  Up	  to	  now,	   the	  correlation	  between	  the	  
enzymatic	  and	  the	  clinical	  phenotype	  of	  PH1	  compound	  heterozygous	  patients	  has	  never	  been	  investigated,	  
although	  they	  represent	  a	  large	  percentage	  of	  PH1	  patients.	  
In	  this	  work,	  for	  the	  first	  time,	  clinical,	  biochemical	  and	  cell	  biology	  data	  have	  been	  collected	  with	  the	  aim	  
of	  understanding	  the	  effects	  of	  the	  S81L	  mutation	  on	  the	  major	  allele	  and	  the	  G170R	  on	  the	  minor	  allele	  
under	  homozygous	  and	  heterozygous	  conditions.	  Our	   investigation	  was	  not	   limited	  to	  the	  AGT	  activity	  of	  
the	  purified	  recombinant	  forms	  of	  S81L-­‐Ma,	  G170R-­‐Mi	  and	  S81L-­‐Ma/G170R-­‐Mi	  and	  to	  the	  specific	  activity	  
upon	  expression	  or	  coexpression	  of	   the	  S81L	  and	  G170R	  variants	   in	  CHO	  cells,	  but	  was	  extended	  to	  their	  
expression	  level,	  coenzyme	  binding	  affinity,	  subcellular	  localization	  and	  functionality.	  This	  broad	  spectrum	  
analysis	  resulted	  to	  be	  useful	  considering	  the	  multiplicity	  of	  the	  molecular	  mechanisms	  accounting	  for	  AGT	  
deficiency.	  The	  results	  gave	  new	  significant	   insights	   into	  the	  PH1	  mechanism,	  as	  we	  report	  the	  molecular	  
basis	  of	  the	  pathogenicity	  of	  the	  S81L	  mutation	  on	  the	  major	  allele	  and	  the	  interplay	  between	  this	  mutation	  
and	   the	   G170R	   mutation	   on	   the	   minor	   allele.	   When	   expressed	   individually	   the	   S81L-­‐Ma	   and	   G170R-­‐Mi	  
variants	  show	  distinct	  features.	  As	  already	  reported	  and	  confirmed	  in	  this	  study,	  when	  only	  G170R-­‐Mi	  allele	  
is	  expressed,	  AGT	  retains	  catalytic	  activity	  and	  PLP	  binding	  affinity,	  but	  it	  is	  almost	  completely	  redirected	  to	  
mitochondria	   (12,	   15,	   17,	   18,	   24,	   25).	  On	   the	   other	   hand,	  we	   here	   report	   that	  when	   the	   S81L-­‐Ma	   allele	  
(lacking	   the	   putative	  MTS)	   is	   expressed,	   AGT	   shows	   a	   decreased	   catalytic	   activity,	   is	   almost	   completely	  
present	  in	  the	  apo	  form,	  and	  is	  mainly	  peroxisomal.	  Thus,	  while	  the	  pathogenicity	  of	  the	  G170R	  mutation	  is	  
related	   to	  AGT	  mistargeting,	   that	  of	   the	   S81L	  mutation	   is	   linked	   to	   the	   reduction	  of	  PLP	  binding	  affinity.	  
What	  happens	  upon	   coexpression	  of	  both	  alleles	   ?	   	  A	  pool	  of	  monomeric	   species	  with	  either	   the	  G170R	  
mutation	  on	   the	  minor	  allele	  or	   the	  S81L	  mutation	  on	   the	  major	  allele	   should	  be	  virtually	  present	   in	   the	  
cytosol.	   In	   theory,	   three	   different	   dimeric	   species,	   homodimers	   G170R-­‐Mi,	   homodimers	   S81L-­‐Ma	   and	  
heterodimers	   G170R-­‐Mi/S81L-­‐Ma	   would	   be	   generated	   from	   the	   combination	   of	   the	   two	   coexpressed	  
monomers.	  We	  were	  able	  to	  recreate	  the	  naturally	  occurring	  mutations	  S81L	  and	  G170R	  in	  AGT	  identified	  
in	   compound	   heterozygous	   patient	   and	   to	   isolate	   and	   characterize	   the	   heterodimer	   in	   the	   purified	  
recombinant	  form.	  This	  allowed	  us	  to	  establish	  that	  it	  exhibits	  a	  considerable	  kcat	  value	  and,	  in	  agreement	  
with	   its	   KD(PLP)	   value,	   it	   is	   present	   in	   the	   cell	   mainly	   in	   the	   holo	   form.	   More	   importantly,	   it	   shows	   a	  
peroxisomal	   localization.	   The	   peroxisome-­‐to-­‐mitochondrion	   mistargeting	   of	   AGT	   in	   PH1	   is	   due	   to	   the	  
combined	   effects	   of	   (i)	   the	   generation	   of	   a	   MTS	   resulting	   from	   the	   P11L	   polymorphism,	   and	   (ii)	   the	  
presence	  of	  monomeric	  AGT.	  Since	  in	  the	  heterodimer	  G170R-­‐Mi/S81L-­‐Ma	  only	  the	  first	  condition	  occurs,	  
even	  if	  limited	  to	  one	  subunit,	  its	  peroxisomal	  localization	  is	  not	  surprising.	  It	  can	  be	  also	  speculated	  that	  in	  
cells	  expressing	  both	  S81L-­‐Ma	  and	  G170R-­‐Mi	   the	   rate	  of	   the	   formation	  of	   the	  heterodimer	   is	   faster	   than	  
that	   of	   the	   import	   of	   G170R-­‐Mi	   monomers	   in	   mitochondria.	   Moreover,	   although	   cells	   expressing	   both	  
G170R-­‐Mi	   and	   S81L-­‐Ma	   show	   a	   reduced	   expression	   level,	   they	   display	   an	   ability	   to	   detoxify	   glyoxylate	  
greater	   than	   that	   of	   cells	   expressing	   homodimer	   S81L-­‐Ma	   and	   equal	   to	   those	   expressing	   homodimers	  
G170R-­‐Mi.	   In	   the	   first	   case,	   this	   could	   be	   interpreted	   on	   the	   basis	   of	   the	   significant	   amount	   of	   protein	  
present	   in	   the	   holo-­‐form.	   In	   the	   second	   case,	   the	   detoxification	   ability	   could	   be	   ascribed	   to	   the	   proper	  
subcellular	  localization	  of	  the	  heterodimer.	  	  
All	   together,	   these	   results	   indicate	   that	   the	   resulting	   hybrid	   protein	   has	   catalytic	   parameters	   not	  
significantly	  different	  from	  those	  obtained	  theoretically	  by	  averaging	  the	  homodimeric	  counterparts,	  and	  a	  
reduced	   expression	   level	   in	   the	   cellular	   system.	   However,	   the	   PLP	   binding	   affinity,	   the	   subcellular	  
localization,	   and	   the	   ability	   to	   detoxify	   glyoxylate	   make	   the	   heterodimer	   more	   functional	   than	   the	  
homodimeric	  counterparts.	  This	  implies	  that	  the	  association	  between	  the	  G170R	  and	  S81L	  monomers	  leads	  
to	   a	   global	   positive	   IC	   between	   these	   mutations.	   On	   these	   bases,	   it	   can	   be	   speculated	   that	   compound	  
heterozygous	   patients	   for	   the	   S81L	  mutation	   on	   the	  major	   allele	   and	   the	  G170R	  mutation	   on	   the	  minor	  
allele	   could	   have	   a	  milder	   phenotype	   than	   homozygous	   S81L	   patients.	   In	   this	   regard,	   although	   it	   is	   not	  
possible	   to	   drawn	   definitive	   conclusions	   only	   from	   two	   patients,	   the	   clinical	   data	   reported	   in	   this	   study	  
appear	  to	  agree	  with	  our	  biochemical	  data.	  Indeed,	  the	  G170R/S81L	  compound	  heterozygous	  patient	  had	  a	  
late	   onset	   of	   ESRD	   compared	   with	   the	   one	   functionally	   hemizygous	   for	   the	   S81L	   mutation	   who	   only	  
expresses	  the	  S81L-­‐Ma	  variant.	  
This	  work	   constitutes	   a	   valid	   example	   of	   an	   approach	   useful	   to	   understand	   the	   enzymatic	   phenotype	   in	  
compound	  heterozygous	  PH1	  patients,	  with	  potential	  applications	  to	  the	  study	  of	  the	  interaction	  between	  
other	   pathogenic	   mutations.	   In	   fact,	   it	   should	   be	   emphasized	   that	   the	   use	   of	   different	   experimental	  
approaches	  has	  been	  crucial	  to	  shed	  light	  on	  the	  molecular	  mechanisms	  of	  IC	  effects	  between	  the	  S81L	  and	  
the	   G170R	   mutation.	   Besides	   providing	   a	   better	   knowledge	   of	   the	   disease	   pathogenesis,	   the	   results	  
obtained	  could	  allow	  to	  develop	  proper	  therapeutic	  treatments,	  as	  the	  hybrid	  protein	  could	  have	  defects	  
different	  from	  those	  of	  the	  parental	  enzymes.	  
	  
	  
Materials	  and	  Methods	  
	  
Materials-­‐	  PLP,	  L-­‐alanine,	  glyoxylate,	  pyruvate,	  rabbit	  muscle	  L-­‐lactic	  dehydrogenase,	  and	  mouse	  anti-­‐FLAG	  
antibody	  were	  purchased	  from	  Sigma	  Aldrich.	  All	  other	  chemicals	  were	  of	  the	  highest	  purity	  available.	  CHO-­‐
GO	   cells,	   the	   rabbit	   polyclonal	   anti-­‐AGT	   human,	   the	   anti-­‐AGT-­‐Ma	   and	   the	   guinea-­‐pig	   anti-­‐peroxisomal	  
protein	   antibodies	   were	   kindly	   provided	   by	   Prof.	   C.J.	   Danpure	   of	   the	   University	   College	   London,	   UK.	  
Oligonucleotides	  were	  purchased	  from	  MWG	  Biotech.	  
Plasmids	   construction-­‐	  To	  obtain	   the	   cDNA	  encoding	   the	  AGT-­‐glutahione	   S-­‐transferase	   (AGT-­‐GST)	   fusion	  
protein,	   the	   human	   AGT	   cDNA	   cloned	   in	   a	   pTrcHis2A	   prokaryotic	   expression	   vector	   (pAGThis)	   (6)	   was	  
provided	  of	  a	  5’	  NcoI	  restriction	  site,	  a	  3’	  thrombin	  cleavage	  site,	  and	  a	  3’	  BamHI	  restriction	  site	  by	  three	  
sequential	  PCR	  amplifications	  using	  the	  forward	  primer	  AGTGSTfwd	  and	  the	  reverse	  primers	  AGTGSTrevA,	  
AGTGSTrevB	   and	   AGTGSTrevC	   (Table	   S1).	   The	   GST	   cDNA	   was	   amplified	   from	   the	   pGEX-­‐4T	   vector	   and	  
provided	  of	  a	  5’	  BamHI	  restriction	  site	  and	  a	  3’	  EcoRI	  restriction	  site	  using	  the	  forward	  primer	  GSTfwd	  and	  
the	   reverse	   primer	   GSTrev	   (Table	   S1).	   The	   two	   amplification	   products	   were	   digested	   with	   the	   BamHI	  
restriction	   enzyme	   and	   ligated	   to	   obtain	   the	   AGTGST	   fusion	   protein	   cDNA.	   To	   construct	   the	   plasmid	  
pAGTGST,	   the	  AGTGST	   cDNA	  was	   subcloned	   into	   the	   pET28a	   vector	   using	   the	  NcoI	   and	   EcoRI	   restriction	  
sites.	  	  
To	  generate	  the	  pAGTFLAG-­‐Ma	  plasmid,	  the	  sequence	  (GATTACAAGGATGACGATGACAAG)	  encoding	  for	  the	  
FLAG	   tag	   (DYKDDDDK)	   was	   introduced	   at	   position	   762	   into	   the	   AGT	   coding	   sequence	   by	  means	   of	   site-­‐
directed	   insertion	  mutagenesis	  using	  the	  pAGThis	  construct	  as	  template,	   the	   insertion	  primers	  AGTFLAG1	  
and	  AGTFLAG2	  (Table	  S1)	  and	  their	  complements.	  
Each	  construct	  was	  confirmed	  to	  be	  free	  of	  mutations	  by	  DNA	  sequencing.	  	  
Site	   directed	  mutagenesis-­‐	   Site-­‐directed	  mutagenesis	  was	   performed	   by	   the	  QuikChange	   II	   site-­‐directed	  
mutagenesis	  kit	  (Stratagene)	  using	  the	  pAGThis-­‐Ma	  (9)	  the	  pAGTFLAG-­‐Ma	  and	  the	  pAGT-­‐GST	  constructs	  as	  
templates	  and	  the	  primers	  reported	  in	  Table	  S1.	  	  
pIRES	  vectors	  construction-­‐	  The	  pIRES	  vector	   is	  a	  bicistronic	  plasmid	   that	  allows	   to	  express	   two	  genes	   in	  
one	   transcript	   in	   mammalian	   cells.	   pIRES	   vectors	   encoding	   two	   copies	   of	   the	   AGT	   cDNA	   in	   different	  
combinations	  (Fig.	  1)	  were	  constructed	  by	  two	  subcloning	  phases.	  In	  the	  first	  phase,	  the	  cDNA	  encoding	  for	  
AGTFLAG-­‐Ma,	   AGTFLAG-­‐Mi,	   AGTFLAG-­‐S81L-­‐Ma	   and	   AGTFLAG-­‐G170RMa,	   obtained	   by	   site-­‐directed	  
mutagenesis	   from	   the	   pAGTFLAG-­‐Ma	   construct,	   were	   subcloned	   in	   the	   first	   polycloning	   site	   using	   the	  
primers	  pIres1fw	  and	  pIres1rev	  (Table	  S1)	  and	  the	  restriction	  enzymes	  NheI	  and	  EcoRI.	  In	  the	  second	  phase,	  
the	   cDNA	   encoding	   for	   AGT-­‐Ma,	   AGT-­‐Mi,	   AGT-­‐S81L-­‐Ma	   and	   AGT-­‐G170R-­‐Mi	   and	   were	   subcloned	   in	   the	  
second	  polycloning	   site	   using	   the	  primers	  pIres2fw	  and	  pIres2rev	   (Table	   S1)	   and	   the	   restriction	  enzymes	  
XbaI	  and	  NotI.	  Each	  construct	  was	  confirmed	  to	  be	  free	  of	  mutations	  by	  DNA	  sequencing.	  	  
Cell	   culture,	   selection	   and	   lysis	   -­‐CHO-­‐GO	   cells	   were	   cultured	   at	   37°C	   under	   O2/CO2	   (19:1)	   in	   Ham's	   F12	  
Glutamax	  medium	  (Invitrogen)	  supplemented	  with	  fetal	  bovine	  serum	  (10%	  v/v),	  penicillin	  (100	  units/ml),	  
streptomycin	   (100	   μg/ml)	   and	   zeocin	   (0.4	   mg/ml).	   Cells	   were	   transfected	   using	   the	   TurbofectTM	  
Transfection	  Reagent	   (Thermo-­‐Fisher).	  After	   24	  h,	  G-­‐418	   (1.25	  mg/ml)	  was	   added	  as	   selective	   agent	   and	  
cells	   were	   left	   to	   grow	   for	   48	   h.	   To	   generate	   monoclonal	   stably	   transformed	   cell	   lines,	   the	   antibiotic-­‐
resistant	  transformants	  were	  seeded	  at	  limiting	  dilution	  of	  10	  cells/ml	  in	  96-­‐well	  plates	  in	  selective	  medium	  
and	   incubated	   until	   single	   colonies	   started	   growing.	   Clones	   (at	   least	   12	   for	   each	   construct)	   were	   then	  
growth	   and	   screened	   for	   exogenous	   gene	   expression	   by	   IFM	   and	   western-­‐blot.	   Cells	   were	   trypsinized,	  
harvested	  and	   lysed	   in	  phosphate	  buffered	   saline	   (PBS),	  pH	  7.2,	  plus	  protease	   inhibitors	   (Complete	  Mini,	  
Roche),	  by	  five	  freeze/thaw	  cycles	  followed	  by	  addition	  of	  DNAse	  (100	  units/ml)	  at	  room	  temperature	  for	  
45	  min.	   The	  whole	   cell	   extract	  was	   then	   centrifuged	   at	   29200	  g	   for	   10	  min	   at	   4°C	   to	   obtain	   the	   soluble	  
cellular	  lysate.	  Protein	  concentration	  was	  determined	  using	  the	  Bradford	  protein	  assay.	  
Enzymatic	  activity	  assays-­‐	  For	  the	  measurement	  of	  AGT	  activity,	  90	  µg	  of	  cell	   lysate	  were	   incubated	  with	  
0.5	  M	  L-­‐alanine	  and	  10	  mM	  glyoxylate	  at	  25°C	   in	  100	  mM	  potassium	  phosphate	  buffer	  (KP)	  pH	  7.4	   in	  the	  
presence	  or	  in	  the	  absence	  of	  200	  µM	  PLP.	  In	  order	  to	  obtain	  a	  detectable	  signal	  of	  pyruvate	  in	  the	  linear	  
phase	  of	  the	  kinetics,	  the	  reaction	  time	  was	  set	  to	  20	  min	  for	  cells	  expressing	  the	  AGT-­‐Ma/AGT-­‐Ma,	  AGT-­‐
Mi/AGT-­‐Ma	  and	  AGT-­‐Mi/AGT-­‐Mi	  constructs,	  and	   to	  60	  min	   for	   cells	  expressing	   the	  other	  constructs.	  The	  
reactions	   were	   stopped	   by	   adding	   TCA	   10%	   (v/v)	   and	   pyruvate	   production	   was	   measured	   using	   a	  
spectrophotometric	  assay	  coupled	  with	  lactate	  dehydrogenase	  as	  previously	  described	  (6).	  
The	  kinetic	  parameters	  for	  the	  overall	  transamination	  of	  the	  pair	  L-­‐alanine/glyoxylate	  of	  normal	  and	  mutant	  
AGT	  were	  determined	  by	   incubating	   the	  purified	  protein	   (0.1	  µM)	   in	   the	  presence	  of	  200	  μM	  PLP	   in	  100	  
mM	  KP	  at	  25°C	  and	  by	  varying	  the	  substrate	  concentration	  at	  a	  fixed	  saturating	  cosubstrate	  concentration.	  
Pyruvate	  formation	  was	  measured	  by	  the	  spectrophotometric	  assay	  already	  reported	  (6).	  Data	  were	  fitted	  
to	  the	  Michaelis–Menten	  equation.	  	  
GO	  enzymatic	  activity	  was	  measured	  by	  incubating	  10	  µg	  of	  cell	  lysate	  with	  4	  mM	  glycolate	  in	  100	  mM	  KP	  
pH	  7.4	  previously	  oxygenated	  and	  equilibrated	  at	  25°C.	  The	  reaction	  was	  stopped	  after	  15	  min	  by	  addition	  
of	   10%	   TCA	   and	   the	   glyoxylate	   produced	   was	   detected	   by	   HPLC	   after	   2,4	   dinitro-­‐phenilhydrazine	  
derivatization	  (30).	  
Transcript	  analysis-­‐	  The	  total	  mRNA	  content	  was	  extracted	  from	  cells	  using	  the	  RNAeasy	  kit	  (Qiagen)	  and	  
analysed	  by	  real-­‐time	  PCR	  as	  described	  in	  SI.	  
Western-­‐blot	   and	   immunoprecipitation-­‐	   Four	   micrograms	   of	   cell	   lysate	   were	   loaded	   per	   lane	   on	   a	  
MiniProtean	   TGXTM	   pre-­‐cast	   gel	   (Biorad)	   along	   with	   the	   Precision	   plus	   protein	   KaleidoscopeTM	   (Bio-­‐Rad)	  
molecular	   mass	   markers.	   Proteins	   were	   transferred	   on	   a	   nitrocellulose	   membrane	   by	   the	   iBlot	   device	  
(Invitrogen)	  and	  the	  membrane	  was	  blocked	  in	  5%	  milk	  solution	  in	  TBST	  (50	  mM	  Tris-­‐HCl	  pH	  7.5,	  150	  mM	  
NaCl,	  0.1%	  Tween	  20)	  for	  1	  h	  at	  RT.	  For	  AGT	  detection	  the	  membrane	  was	  incubated	  with	  polyclonal	  rabbit	  
anti	   AGT	   serum	   (dilution	   1:6000),	   washed	   three	   times	   in	   TBST	   and	   then	   incubated	   with	   peroxidase-­‐
conjugated	  anti	  rabbit	  IgG	  (dilution	  1:10000).	  Blotted	  proteins	  were	  detected	  with	  ECLTM	  (Millipore),	  using	  
the	  ChemiDocXRS	  Imaging	  System	  (Bio-­‐Rad,	  Hercules,	  CA).	  Densitometry	  analysis	  was	  performed	  using	  the	  
software	  ImageJ.	  For	  immunoprecipitation,	  300	  µg	  of	  cell	   lysates	  were	  incubated	  overnight	  with	  300	  µl	  of	  
PBS	   buffer	   supplemented	   with	   3	   μg	   of	   mouse	   anti-­‐FLAG	   IgG	   .	   The	   solutions	   were	   then	   incubated	   with	  
Protein-­‐A-­‐Sepharose	   for	   1	   h	   and	   the	   protein-­‐antibody	   complexes	   were	   recovered	   by	   centrifugation.	  
Samples	   were	   washed	   three	   times	   with	   PBS	   and	   analysed	   by	   western-­‐blot	   using	   a	   rabbit	   anti-­‐AGT-­‐Ma	  
antiserum	  (1:1000).	  
Glycolate	  toxicity	  assay-­‐	  The	  glycolate	  toxicity	  assay	  was	  performed	  as	  previously	  reported	  (15).	  CHO-­‐GO	  
cells	   were	   seeded	   at	   7.000	   cells/well	   in	   a	   96-­‐wells	   plate	   and	   incubated	   24	   h	   before	   inducing	   glyoxylate	  
production	  by	  adding	  Hepes	  buffered	  glycolate	  pH	  7.0	  at	  a	  final	  concentration	  of	  250	  µM.	  Cell	  viability	  was	  
evaluated	  after	  further	  24	  h	   incubation	  using	  the	  crystal	  violet	  staining	  (Sigma	  Aldrich).	  Briefly,	  cells	  were	  
rinsed	  with	  PBS,	   incubated	  at	   room	  temperature	   for	  5	  min	  with	  4	  %	   formaldehyde	  +	  0.5	  %	  Crystal	  Violet	  
solution	  to	  perform	  fixing	  and	  staining.	  Cells	  were	  then	  extensively	  washed	  with	  distilled	  water	  to	  remove	  
the	  excess	  of	  dye	  and	  lysed	  with	  1	  %	  SDS	  in	  PBS	  to	  allow	  crystal	  violet	  solubilisation	  and	  quantification.	  The	  
absorbance	  at	  595	  nm,	  which	   is	  proportional	   to	   the	  number	  of	  viable	  cells,	  was	  measured	  with	  a	  TECAN	  
plate	   reader.	   Six	   replicates	  were	   performed	   for	   each	   assay	   condition.	   Statistical	   analysis	   was	   performed	  
with	  GraphPad	  Prism	  Version	  5.0	  (GraphPad	  software,	  San	  Diego,	  CA,	  USA).	  
IFM-­‐	   3	   x	   105	   cells	   were	   grown	   for	   24	   hours	   into	   a	   13-­‐mm	   glass	   coverslip	   on	   a	   24-­‐well	   plate.	   For	   the	  
mitochondrial	  labelling,	  cells	  were	  vitally	  stained	  for	  30	  min	  with	  MitoTracker	  Red	  (Molecular	  Probes).	  Cells	  
were	  fixed	  in	  4%	  (w/v)	  paraformaldehyde,	  permeabilized	  with	  0.3%	  Triton	  X-­‐100	  in	  PBS	  and	  then	  blocked	  in	  
3%	  bovine	  serum	  albumine.	  For	  the	  immunolabelling,	  rabbit	  polyclonal	  anti-­‐human	  AGT,	  anti-­‐peroxisomal	  
protein	   form	   guinea-­‐pig	   and	   mouse	   monoclonal	   anti-­‐FLAG	   were	   used	   as	   primary	   antibodies,	   and	   Alexa	  
Fluor	   conjugated	   antibodies	   (AF488	   and	   AF555,	   Life	   technologies)	   were	   used	   as	   secondary	   antibodies.	  
Nuclei	   were	   stained	   with	   DAPI	   (Molecular	   Probes)	   and	   the	   coverslips	   were	  mounted	   over	   slides	   in	   AF1	  
medium	  (Dako).	  The	  images	  were	  captured	  using	  a	  confocal	   laser-­‐scanning	  fluorescence	  microscope	  Leica	  
SP5	   (Molecular	   Probes,	   Leica	  Microsystem)	   at	   63×	  magnification.	   Pearson’s	   coefficients	   were	   calculated	  
using	   the	   ImageJ	   (http://rsb.info.nih.gov/ij/)	   JACoP	   plugin	   and	   images	   were	   processed	   using	   Adobe	  
Photoshop.	  	  
Expression	   and	   purification-­‐	   The	   his-­‐tagged	   AGT-­‐Ma,	   AGT-­‐Mi,	   G170R-­‐Mi,	   and	   S81L-­‐Ma	   variants	   were	  
expressed	   in	   E.	   coli	   and	   purified	   as	   already	   described	   (6).	   The	   S81L-­‐Ma/G170R-­‐Mi	   heterodimers	   were	  
obtained	   by	   co-­‐transforming	   E.	   coli	   BL21	   (DE3)	   cells	   with	   vectors	   encoding	   the	   GST-­‐tagged	   G170R-­‐Mi	  
variant	  and	  the	  his-­‐tagged	  S81L-­‐Ma	  variant	  and	  purified	  by	  a	  Ni-­‐affinity	  chromatography	  followed	  by	  a	  GST-­‐
affinity	  chromatography.	  Details	  are	  given	   in	  SI.	  The	  apo-­‐form	  of	  each	  variant	  was	  prepared	  as	  previously	  
described	  (6).	  The	  protein	  concentration	  in	  the	  AGT	  samples	  was	  determined	  using	  an	  extinction	  coefficient	  
of	  9.54	  ×	  104	  M−1	  cm−1	  at	  280	  nm	  (6).	  	  
Determination	  of	  KD(PLP)-­‐	  The	  KD(PLP)	  values	  of	  heterodimeric	  S81L-­‐Ma/G170R-­‐Mi	  and	  of	  homodimeric	  S81L-­‐
Ma	  was	  determined	  by	  measuring	   the	  quenching	  of	   the	   intrinsic	   fluorescence	  of	   the	  apoenzyme	  and	  the	  
change	   of	   the	   CD	   signal	   at	   430	   nm,	   respectively,	   	   in	   the	   presence	   of	   PLP	   at	   varying	   concentrations,	   as	  
described	  in	  SI.	  
Spectroscopic	  measurements-­‐	  Absorption,	  fluorescence,	  and	  CD	  spectra	  were	  registered	  as	  described	  in	  SI.	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Legends	  to	  figures	  
	  
Figure	  1	  Graphical	  sketch	  of	  the	  bicistronic	  pIRES	  constructs	  expressing	  the	  AGT	  variants.	  The	  first	  ORF	  is	  
bearing	  the	  FLAG	  sequence.	  Polymorphic	  and	  pathogenic	  mutations	  in	  each	  construct	  are	  marked	  grey	  and	  
black,	  respectively.	  
	  
Figure	  2.	  Western-­‐blot	  and	  specific	  activity	  analyses	  of	  CHO-­‐GO	  cell	  clones	  expressing	  the	  AGT	  variants.	  4	  
µg	   of	   cell	   lysate	   were	   immunoblotted	   with	   (A)	   anti-­‐AGT	   from	   rabbit	   and	   anti-­‐rabbit	   HRP-­‐conjugated	  
antibodies,	   and	   (B)	   mouse	   anti-­‐FLAG	   and	   anti-­‐mouse	   HRP-­‐conjugated	   antibodies.	   Lanes:	   1.	   CHO-­‐GO;	   2.	  
AGT-­‐Ma/AGT-­‐Ma;	  3.	  AGT-­‐Mi/AGT-­‐Mi;	  4.	  AGT-­‐Mi/AGT-­‐Ma;	  5.	  G170R-­‐Mi/G170R-­‐Mi;	  6.	  S81L-­‐Ma/S81L-­‐Ma;	  7.	  
G170R-­‐Mi/S81L-­‐Ma.	  (C)	  100	  µg	  of	  cell	  lysate	  were	  incubated	  with	  0.5	  M	  L-­‐alanine	  and	  10	  mM	  glyoxylate	  at	  
25	  °C	  in	  100	  mM	  potassium	  phosphate	  buffer,	  pH	  7.4	  in	  the	  presence	  (black)	  or	  in	  the	  absence	  (white)	  of	  
200	  µM	  PLP.	  Data	  are	  representative	  of	  three	  independent	  experiments.	  Bar	  graphs	  represent	  the	  mean	  ±	  
S.D.	  	  
	  
Figure	  3.	  Identification	  of	  the	  presence	  of	  heterodimeric	  forms	  of	  AGT	  by	  immunoprecipitation.	  300	  µg	  of	  
cell	  lysate	  were	  immunoprecipitated	  using	  an	  anti-­‐FLAG	  antibody	  and	  detected	  by	  western-­‐blot	  using	  rabbit	  
anti-­‐AGT-­‐Ma	   and	   anti-­‐rabbit	   HRP-­‐conjugated	   antibodies.	   Lanes:	   1.	   	   purified	   AGT-­‐Ma	   control	   non-­‐
immunoprecipitated;	   2.	   CHO-­‐GO	   parental	   cells;	   3.	   AGT-­‐Mi/AGT-­‐Mi;	   4.	   G170R-­‐Mi/G170R-­‐Mi;	   5.	   AGT-­‐
Mi/AGT-­‐Ma;	  6.	  G170R-­‐Mi/S81L-­‐Ma.	  
	  
Figure 4. Subcellular distribution of G170R-Mi/G170R-Mi, S81L-Ma/S81L-Ma and G170R-
Mi/S81L-Ma variants in stably transformed CHO-GO cells. Twenty-four hours after seeding 
cells were fixed and colored as follow: (A) anti-AGT (green) and anti-peroxisomal proteins (red) 
and (B) anti-FLAG (green) and anti-peroxisomal proteins (red). Nuclei were stained with Dapi 
(blue). Below is shown the RGB profile plotted along the line drawn in the merged image. Merge 
and single channel images come from a single z-plane. Scale bar: 10 µm. 
 
Figure 5. Subcellular distribution of G170R-Mi/G170R-Mi, S81L-Ma/S81L-Ma and G170R-
Mi/S81L-Ma variants in stably transformed CHO-GO cells. Twenty-four hours after seeding 
cells were fixed and colored as follow: (A) anti-AGT (green) and MitoTracker (red) and (B) anti-
FLAG (green) and MitoTracker (red). Nuclei were stained with Dapi (blue).  Below is shown the 
RGB profile plotted along the line drawn in the merged image. Merge and single channel images 
come from a single z-plane. Scale bar: 10 µm. 
 
Figure 6. Pearson’s coefficients for the subcellular distribution of the analyzed AGT variants 
in stably transformed CHO-GO cells. The histogram bars represent the Pearson’s coefficient 
calculated for the colocalization of: AGT and mitochondria (solid black), AGT and peroxisomes 
(outlined black), AGT-FLAG and mitochondria (solid gray), AGT-FLAG and peroxisomes 
(outlined gray). The results are given as means (± S.E.M.) of several images; at least 30 individual 
cells were analyzed for each coefficient. 
 
Figure 7. Glycolate cytotoxicity assay of CHO-GO cells expressing the AGT variants.  
The histogram is representative of the cell viability after 24 h of treatment with 250 µM glycolate  






Table	  1.	  Kinetic	  parameters	  and	  KD(PLP)	  values	  of	  the	  AGT	  variants	  








AGT-­‐Maa	   0.27	  ±0.03	   45	  ±	  2	   31	  ±	  4	   0.23	  ±	  0.05	  
AGT-­‐Mib	   0.26	  ±	  0.02	   37	  ±	  5	   28	  ±	  2	   0.22	  ±	  0.01	  
G170R-­‐Mic	   0.4	  ±	  0.1	   34	  ±	  3	   36	  ±	  2	   0.4	  ±	  0.1	  
S81L-­‐Ma	   17	  ±	  3	   13.9	  ±	  0.9	   40	  ±	  8	   0.16	  ±0.02	  
G170R-­‐Mi/	   1.2	  ±	  0.1	   18.3	  ±	  0.6	   45	  ±	  3	   0.18	  ±	  0.02	  
S81L-­‐Ma	  






PH1:	  Primary	  Hyperoxaluria	  Type	  I;	  AGT:	  alanine:glyoxylate	  aminotransferase;	  PLP:	  pyridoxal	  5’-­‐phosphate;	  
ESRD:	  End	  stage	  renal	  disease;	  MTS:	  mitochondrial	   targeting	  sequence;	  CHO:	  chinese	  hamster	  ovary;	  GO:	  
glycolate	   oxidase;	   PBS:	   phosphate	   buffered	   saline;	   KD(PLP):	   PLP	   equilibrium	   dissociation	   constant;	   KP:	  
Phosphate	  buffer;	  IC:	  interallelic	  complementation.	  
	  
	  
